October 18, 2016
Investment opportunitiesAn overview of the developing and emerging portfolios
Carmen Nitsche and John Wise
Partner logo if required
© P
istoi
a Al
lianc
e
2
Agenda
• Introducing new Portfolio Investment committee
• Developing portfolio– Unified chemistry data model– User experience/User centered design – Sequence analysis in the regulated domain
• Emerging portfolio– Wearables – Real-world data platform – IoT
• Other discussion topics– Identification of medicinal products (IDMP) – Non-Clinical Development Community of Interest – Blockchain
Standards• UDM• Wearables
Data sharing• RWD platforms• IoT• Non-clinical development
Best practices• UXUCD• Seq an. In reg dom • IDMP• Blockchain
© P
istoi
a Al
lianc
e
3
Introducing Portfolio Investment committee
Operations Board
Investment committee
Innovation committee
Advisory Panel
David Murray AZ
Angeli MöllerBayer
David NirschlBMS
Devendra DeshmukhMerck & Co
Simon ThornberGSK
Veit UlshoeferMerck Group
Mohit AgnihotriNovartis
Tom PiankoElsevier
© P
istoi
a Al
lianc
e
Developing PortfolioStandards• UDM
Data sharing
Best practices• UXUCD• Seq analysis (reg domain)
4
© P
istoi
a Al
lianc
e
Unified [chemistry] data model (UDM)
+Problem Statement: Collaboration and chemical information data exchange with partners and CROs is hampered when different ELNs are in use.• No common data model to describe chemical reactions • Thwarting the development/sharing of business rules for consistent
representation of reactions and IP capture
VARIATIONS STAGES+ +
5
Standards•UDM
Data sharingBest practices
© P
istoi
a Al
lianc
e
6
Unified chemistry data model
• Status– Community of interest
established– Excellent example of
cross-community involvement
– Introductory materials posted on IP3
– Domain-aware, experienced PM hired
– Biz case underway• Jarek Tomczak
beginning interviews with stakeholders
• Next steps– Complete
biz case– Establish budget req.– Fundraise
• Estimate $150K required• Several pledges in
process• If this is of interest to
you:• Join the CoI• Contribute use-cases• Make a pledge!
Standards•UDM
Data sharingBest practices
© P
istoi
a Al
lianc
e
7
User experience/User centered designStandardsData sharing
Best practices•UXUCD
Problem Statement: “R&D in Pharma is quite hard enough without R&D IT getting in the way!”
(personal communication from a senior leader in R&D from a major biopharma company)
© P
istoi
a Al
lianc
e
8
User experience/User centered design
• Status– Active CoI– ~40 people/20 companies
at F-2-F joint EMBL-EBI workshop (Sep-16)
– 1st round fund-raising in process. $25K raised from:
• Bayer• GSK• Novartis• Roche• quattro research• (still in discussion with
others)
• Next steps– Contract a
domain-aware, experienced PM.
– Complete fundraising• Looking for $5K/co.
– Launch Phase 1• Build 3 high-priority
UX/UCD tools, • If this is of interest
to you:• Join project team• Make a pledge!
StandardsData sharing
Best practices•UXUCD
© P
istoi
a Al
lianc
e
Sequence analysis in regulated domain
9
StandardsData sharing
Best practices• Seq analysis (reg domain)
Problem Statement: As sequence analysis becomes increasingly a part of clinical trials - so sequence analysis enters the realms of GCP, and must become compliant with all the concomitant regulations controlling the use of computer-based technologies, including 21 CFR Part 11 and Computer Systems Validation.
© P
istoi
a Al
lianc
e
10
Sequence analysis in regulated domain
• Status– Idea entered into
IP3– CoI emerging– Webinar on topic
presented in Sept 2016
– $20K seed money contributed by Roche to support concept development
• Next steps– Contract a
domain-aware, experienced PM.
– Identify needs and develop business case
• If this is of interest to you:– Join the CoI– Help refine/prioritize
the needs– Make a pledge!
StandardsData sharing
Best practices• Seq analysis (reg domain)
© P
istoi
a Al
lianc
e
Emerging PortfolioStandards• Wearables
Data sharing• RWD platforms• IoT
Best practices
11
© P
istoi
a Al
lianc
e
Wearables
12
Problem Statement: There is an increasing use of wearables to collect phenotypic data in clinical trials. However, there are few standards to harmonise the data formats for transmission and storage of such data in clinical trials databases. This Community of Interest is working to understand how the Pistoia Alliance can identify best practices and “signpost” appropriate data and information standards.
Standards•Wearables
Data sharingBest practices
© P
istoi
a Al
lianc
e
13
Wearables
• Status– Wearables are a hot
topic our members are highlighting
– Conference session at PA 2016 conference London
– 2 webinar hosted in 2016
• Smart glasses• Clinical trials&
wearables– Initial idea entered
into IP3
• Next steps– Develop the
CoI– Submit idea to
investment committee
• Seed $ to hire PM• If this is of interest
to you:– Join the CoI– Make a pledge!
Standards•Wearables
Data sharingBest practices
© P
istoi
a Al
lianc
e
Real-world data
14
Problem Statement: The need for real world data (RWD) means a need for rapid integration of structured, semi-structured and unstructured data. Individual approaches are suboptimal. This community of interest will explore what is needed to create a more shared RWD environment, to improve access and mining of such data.
Standards
Data sharing• RWD platforms
Best practices
© P
istoi
a Al
lianc
e
15
Real-world data
• Status– Idea submitted to
IP3– Preliminary polling
of PA members suggests broad interest in topic
– New position paper submitted to PA comms company
• Next steps– Organize a PA
debates webinar – Establish a CoI
• Share case studies• Discuss requirements• Identify best practices and • opportunities for
precompetitive collaboration– Submit idea to investment
committee• If this is of interest to you:
– Join the CoI– Comment on IP3 to help
focus the discussion– Make a pledge!
Standards• Wearables
Data sharing• RWD platforms• IoT
Best practices
© P
istoi
a Al
lianc
e
Internet of Things (IoT)
16
Problem Statement: Internet of Things is still an immature field within Pharma. This community of interest will share use cases and identify tangible, common opportunities, including those in the laboratory, that could be addressed with a pre-competitive model.
Standards
Data sharing• IoT
Best practices
© P
istoi
a Al
lianc
e
17
Internet of Things (IoT)
• Status– Preliminary idea
entered into IP3– Session at 2016 PA
conference in Boston
• Next steps– Establish CoI
• Share case studies• Identify best practices &• opportunities for
precompetitive collaboration
– Submit idea to investment committee
• If this is of interest to you:– Join the CoI– Share case studies– Make a pledge!
Standards
Data sharing• IoT
Best practices
© P
istoi
a Al
lianc
e
Other discussion topics
Standards
Data sharing• Non-clinical development
Best practices• IDMP• Blockchain
18
© P
istoi
a Al
lianc
e
IDMP
19
Problem Statement: Mandatory implementation of IDMP (identification of medicinal products - the ISO standard) is upon us. The Pistoia Alliance has the capability to identify pre-competitively and define best practices to implement this standard across the R&D pipeline through establishment of a Community of Interest.
StandardsData sharing
Best practices• IDMP
© P
istoi
a Al
lianc
e
20
IDMP
• Status– Personal
communication with a regulatory agency official... “What is the Pistoia Alliance doing about IDMP?”
– Write-up being prepared
• Next steps– Establish CoI– Submit idea to
investment committee• If this is of interest to
you:– Consider championing
the idea!– Submit comments to
IP3– Join the CoI– Make a pledge!
StandardsData sharing
Best practices• IDMP
© P
istoi
a Al
lianc
e
Non-clinical development CoI (NCD CoI)
21
Problem Statement: Currently, there is no cross-industry community of interest focusing on optimizing non-clinical development processes. For example, Much time and money is expended by NCD functions replicating protocol creation and validation. Collaborating in this area could save time, decrease costs and increase quality.
Standards
Data sharing• Non-clinical development
Best practices
© P
istoi
a Al
lianc
e
22
Non-clinical development CoI
• Status– Initial IP3 idea
submitted– F2F discussion
planning underway
• Next steps– Hold first CoI
meeting in November
– Submit idea to investment committee
• If this is of interest to you:– Join the CoI– Submit discussion
topics on IP3– Make a pledge!
Standards
Data sharing• Non-clinical development
Best practices
© P
istoi
a Al
lianc
e
Blockchain
23
Problem Statement: Blockchain has come on our radar recently, but we don’t know enough about it yet. For example can it enhance compliance in clinical trials and the clinical trials supply chain? If this topic is of interest to you, please let us know and consider entering your thoughts into IP3.
StandardsData sharing
Best practices• Blockchain
[email protected] @pistoiaalliance www.pistoiaalliance.org